What is De Novo Software?
De Novo Software is a premier provider of FCS Express, a sophisticated software platform engineered for the comprehensive analysis, statistical evaluation, and visualization of flow cytometry data. By bridging the gap between complex data management and user-friendly interface design, the company has successfully democratized access to high-level cytometry workflows. Its product suite is specifically tailored to meet the rigorous demands of clinical diagnostic laboratories, academic research institutions, and the rapidly evolving cell and gene therapy sectors.
The company distinguishes itself through a commitment to workflow automation and intuitive design, mirroring the familiarity of standard office productivity suites to minimize user friction. With a global user base numbering in the thousands, De Novo Software maintains a dominant market position by prioritizing exceptional technical support and continuous innovation in data reporting standards.
How much funding has De Novo Software raised?
De Novo Software has raised a total of $855K across 2 funding rounds:
Debt
$350K
Debt
$505K
Debt (2020): $350K with participation from PPP
Debt (2021): $505K led by PPP
Key Investors in De Novo Software
PPP
Public-Private Partnership
What's next for De Novo Software?
With this major strategic investment now secured, De Novo Software is poised to enter a new phase of enterprise-level scaling. The company is expected to focus its resources on deepening its integration capabilities within clinical diagnostic environments and expanding its suite of automated reporting tools for cell and gene therapy researchers. By optimizing its internal infrastructure and enhancing its software architecture, the firm aims to solidify its status as the industry standard for cytometry data management.
Strategic priorities will likely include the expansion of its global support network and the pursuit of further technological advancements that streamline the transition from raw data to actionable clinical insights. As the life sciences industry continues to prioritize data integrity and workflow efficiency, De Novo Software remains strategically aligned to capture additional market share and drive long-term value for its stakeholders.
